Anacor Scores $100M In Valeant Fungus Drug Feud
Valeant Pharmaceuticals International Inc. has been ordered to cough up $100 million to Anacor Pharmaceuticals Inc. in arbitration over a contract dispute concerning Valeant's developmental nail fungus treatment, the companies said...To view the full article, register now.
Already a subscriber? Click here to view full article